Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia

Overview of attention for article published in Frontiers in Pharmacology, June 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 2 publications that cite this research output.

2

The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.

Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction

Article in PLOS ONE (August 2024)

Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam – findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model

Article in Journal of Medical Economics (July 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.